Recarbrio Side Effects

Generic name: cilastatin / imipenem / relebactam

Medically reviewed by Drugs.com. Last updated on Aug 7, 2024.

Note: This document provides detailed information about Recarbrio.

Applies to cilastatin / imipenem / relebactam: intravenous powder for solution Side Effects associated with cilastatin / imipenem / relebactam. Some dosage forms listed on this page may not apply specifically to the brand name Recarbrio.

Applies to cilastatin / imipenem / relebactam: intravenous powder for solution.

Precautions

It is very important that your doctor check your progress closely while you are receiving this medicine. This is to make sure that the medicine is working properly and that the infection is cleared up completely. Blood and urine tests may be needed to check for unwanted effects.

This medicine may cause serious types of allergic reactions, including anaphylaxis. Anaphylaxis can be life-threatening and requires immediate medical attention. Tell your doctor or nurse right away if you have itching, hives, hoarseness, trouble breathing, trouble swallowing, or any swelling of your hands, face, or mouth after you receive this medicine.

Some patients may develop seizures while receiving this medicine. If you already have had stroke or a history of seizures and you are taking anticonvulsants, you should continue to take them unless otherwise directed by your doctor. Tell your doctor if you are also using divalproex sodium (Depakote®) or valproic acid (Depakene®).

This medicine may cause diarrhea, and in some cases it can be severe. It may occur 2 months or more after you stop receiving this medicine. Do not take any medicine to treat diarrhea without first checking with your doctor. Diarrhea medicines may make the diarrhea worse or make it last longer. If you have any questions about this or if mild diarrhea continues or gets worse, check with your doctor.

Do not take other medicines unless thy have been discussed with your doctor. This includes prescription or nonprescription (over-the-counter [OTC]) medicines and herbal or vitamin supplements.

Serious side effects of Recarbrio

Along with its needed effects, cilastatin/imipenem/relebactam may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking cilastatin / imipenem / relebactam:

Other side effects of Recarbrio

Some side effects of cilastatin / imipenem / relebactam may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

For healthcare professionals

Applies to cilastatin / imipenem / relebactam: intravenous powder for injection.

Hepatic adverse events

• Very common (10% or more): Increased AST (up to 11.7%)
• Common (1% to 10%): Increased ALT

Imipenem-cilastatin:

• Common (1% to 10%): Increased ALT, increased AST
• Uncommon (0.1% to 1%): Increased serum bilirubin
• Rare (0.01% to 0.1%): Hepatic failure, hepatitis
• Very rare (less than 0.01%): Fulminant hepatitis
• Frequency not reported: Jaundice^[Ref]

Hematologic

• Very common (10% or more): Anemia (included anemia, decreased hemoglobin; up to 10.5%)
• Frequency not reported: Thrombocytopenia

Imipenem-cilastatin:

• Common (1% to 10%): Anemia, eosinophilia
• Uncommon (0.1% to 1%): Pancytopenia, neutropenia, leukopenia, thrombocytopenia, thrombocytosis, positive Coombs test, prolonged prothrombin time, decreased hemoglobin
• Rare (0.01% to 0.1%): Agranulocytosis
• Very rare (less than 0.01%): Hemolytic anemia, bone marrow depression
• Frequency not reported: Increased eosinophils, increased eosinophil count^[Ref]

Metabolic

• Common (1% to 10%): Hypokalemia (included hypokalemia, decreased blood potassium), hyponatremia (included hyponatremia, decreased blood sodium)

Gastrointestinal

• Common (1% to 10%): Diarrhea, nausea, vomiting, increased lipase, constipation
• Frequency not reported: Clostridioides difficile-associated diarrhea

Imipenem-cilastatin:

• Common (1% to 10%): Nausea, diarrhea, vomiting, increased lipase
• Rare (0.01% to 0.1%): Pseudomembranous colitis, staining of teeth and/or tongue
• Very rare (less than 0.01%): Gastroenteritis, hemorrhagic colitis, abdominal pain, heartburn, glossitis, tongue papilla hypertrophy, increased salivation^[Ref]

Dermatologic

• Common (1% to 10%): Rash (included rash, erythematous rash, generalized rash)

Imipenem-cilastatin:

• Common (1% to 10%): Rash (e.g., exanthematous)
• Uncommon (0.1% to 1%): Urticaria, pruritus
• Rare (0.01% to 0.1%): Toxic epidermal necrolysis, angioedema, Stevens-Johnson syndrome, erythema multiforme, exfoliative dermatitis
• Very rare (less than 0.01%): Hyperhidrosis, skin texture changes^[Ref]

Other

• Common (1% to 10%): Pyrexia

Imipenem-cilastatin:

• Common (1% to 10%): Pyrexia, increased serum alkaline phosphatase
• Rare (0.01% to 0.1%): Candidiasis
• Very rare (less than 0.01%): Chest discomfort, asthenia/weakness
• Frequency not reported: Increased blood lactate dehydrogenase^[Ref]

Nervous system

• Common (1% to 10%): Headache
• Uncommon (0.1% to 1%): Central nervous system (CNS) adverse reactions (included agitation, apathy, confusional states, delirium, disorientation, slow speech, somnolence)

Imipenem-cilastatin:

• Common (1% to 10%): Headache, CNS adverse reactions
• Uncommon (0.1% to 1%): Seizures, myoclonic activity, dizziness, somnolence
• Rare (0.01% to 0.1%): Encephalopathy, paresthesia, focal tremor, taste perversion, hearing loss
• Very rare (less than 0.01%): Aggravation of myasthenia gravis, vertigo, tinnitus
• Frequency not reported: Dyskinesia^[Ref]

Local

• Common (1% to 10%): Phlebitis/infusion site reactions (included infusion site phlebitis, infusion site erythema, infusion site pain)

Imipenem-cilastatin:

• Common (1% to 10%): Phlebitis/infusion site reactions
• Uncommon (0.1% to 1%): Local pain and induration at injection site^[Ref]

Cardiovascular

• Common (1% to 10%): Hypertension (included hypertension, increased blood pressure)

Imipenem-cilastatin:

• Common (1% to 10%): Hypertension, thrombophlebitis
• Uncommon (0.1% to 1%): Hypotension
• Very rare (less than 0.01%): Cyanosis, tachycardia, palpitations, flushing^[Ref]

Renal

• Uncommon (0.1% to 1%): Increased blood creatinine, decreased creatinine renal clearance

Imipenem-cilastatin:

• Common (1% to 10%): Increased blood creatinine
• Uncommon (0.1% to 1%): Increased blood urea nitrogen
• Rare (0.01% to 0.1%): Acute renal failure^[Ref]

Psychiatric

Imipenem-cilastatin:

• Uncommon (0.1% to 1%): Hallucinations, confusional states
• Frequency not reported: Agitation^[Ref]

Hypersensitivity

Imipenem-cilastatin:

• Rare (0.01% to 0.1%): Anaphylactic reactions

Beta-lactams:

• Frequency not reported: Hypersensitivity (anaphylactic) reactions^[Ref]

Genitourinary

Imipenem-cilastatin:

• Rare (0.01% to 0.1%): Oliguria/anuria, polyuria, urine discoloration
• Very rare (less than 0.01%): Pruritus vulvae^[Ref]

Urine discoloration was harmless (not to be confused with hematuria).^[Ref]

Respiratory

Imipenem-cilastatin:

• Very rare (less than 0.01%): Dyspnea, hyperventilation, pharyngeal pain^[Ref]

Musculoskeletal

Imipenem-cilastatin:

• Very rare (less than 0.01%): Polyarthralgia, thoracic spine pain^[Ref]

See also:

Further information

Recarbrio side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.

Medical Disclaimer